A Review of Proteomic Studies in Uterine Leiomyosarcoma: Biomarkers, Pathways, and Clinical Potential
Areti Kourti, Andigoni Malousi, Konstantina Psatha, Ioannis Kalogiannidis, Michalis Aivaliotis, Elisavet Georgiou · 2026
Read A Review of Proteomic Studies in Uterine Leiomyosarcoma: Biomarkers, Pathways, and Clinical Potential by Areti Kourti, Andigoni Malousi, Konstantina Psatha, Ioannis Kalogiannidis, Michalis Aivaliotis, Elisavet Georgiou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13605825.txt.
Description
Kourti and co-authors review protein studies of a rare womb cancer in a 2026 paper. Uterine leiomyosarcoma grows fast, returns often, and resists most drug care. Telling it apart from benign growths is hard. Protein-wide scans, called proteomics, now offer a fresh window on its biology.
The review gathers scans that map which proteins run high or low in the tumors. Shifts cluster in energy use, cell cycle control, tissue scaffolding, and drug resistance. Some protein marks may help split the cancer from benign lumps. Others point to fresh drug targets in growth signals and the tumor setting. The authors close with gaps to close before such findings reach clinic use.
Catalog record
| CREATOR | Areti Kourti, Andigoni Malousi, Konstantina Psatha, Ioannis Kalogiannidis, Michalis Aivaliotis, Elisavet Georgiou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |